Protein-Protein Interactions

  • Michael D. Wendt

Part of the Topics in Medicinal Chemistry book series (TMC, volume 8)

Table of contents

  1. Front Matter
    Pages i-xviii
  2. Michael D. Wendt
    Pages 1-55
  3. Shaomeng Wang, Yujun Zhao, Denzil Bernard, Angelo Aguilar, Sanjeev Kumar
    Pages 57-79
  4. Kurt Deshayes, Jeremy Murray, Domagoj Vucic
    Pages 81-103
  5. John F. Kadow, David R. Langley, Nicholas A. Meanwell, Richard Pracitto, Michael A. Walker, Kap-Sun Yeung
    Pages 105-165
  6. Andrew B. Mahon, Stephen E. Miller, Stephen T. Joy, Paramjit S. Arora
    Pages 197-230
  7. Back Matter
    Pages 259-261

About this book


Michael D. Wendt
Protein-Protein Interactions as Drug Targets

Shaomeng Wang , Yujun Zhao , Denzil Bernard , Angelo Aguilar , Sanjeev Kumar
Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics

Kurt Deshayes , Jeremy Murray , Domagoj Vucic
The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer

John F. Kadow , David R. Langley , Nicholas A. Meanwell , Michael A. Walker , Kap-Sun Yeung , Richard Pracitto
Protein-Protein Interaction Targets to Inhibit HIV-1 Infection

Nicholas A. Meanwell , David R. Langley
Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion – a Focus on Respiratory Syncytial Virus

Andrew B. Mahon , Stephen E. Miller , Stephen T. Joy , Paramjit S. Arora
Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces

Michael D. Wendt
The Discovery of Navitoclax, a Bcl-2 Family Inhibitor


drug discovery inhibitors protein-protein interactions

Editors and affiliations

  • Michael D. Wendt
    • 1
  1. 1., Global Pharmaceutical R & DAbbott LaboratoriesAbbott ParkUSA

Bibliographic information